The first patient has been dosed in the DESTINY-Gastric05 phase IIII trial evaluating Enhertu (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s anti-PD-1… read more.
Gastric cancer (GC), commonly known as stomach cancer, ranks as the world’s fifth most common cancer and the third leading cause of cancer-related deaths, claiming over 784,000 lives… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
